Tokyo, Dec. 23 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060168) titled 'Survey on How the Implementation of a Hypertension Digital Therapeutic in Medical Facilities Affects Patients' Healthcare Utilization' on Dec. 22.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - CureApp, Inc.
Condition:
Condition - Hypertension
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Evaluate the impact of introducing the therapeutic SaMD (CureApp HT) on patient treatment behavior, specifically new visits and follow-up visits, at the healthcare institution implementing it.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Questionnaire A (General Hypertension Patients):Adult hypertension patients who meet the diagnostic criteria for hypertension and are currently receiving treatment at a medical institution or have received treatment in the past.
Survey B (Hypertension Patients Using SaMD):Currently undergoing hypertension treatment using CureApp HT and has received guidance from a physician at least once based on their own input.
Key exclusion criteria - Survey A (General Hypertension Patients):Patients who have received treatment with CureApp HT in the past or currently.
Survey B (Hypertension Patients Using SaMD):-
Target Size - 600
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2025 Year 10 Month 21 Day
Date of IRB - 2025 Year 12 Month 16 Day
Anticipated trial start date - 2025 Year 12 Month 22 Day
Last follow-up date - 2026 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068809
Disclaimer: Curated by HT Syndication.
